Drugs / YYD302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02965495 | Nov 2016 → Sep 2017 | osteoarthritis, knee | Yooyoung Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03561779 | Feb 2018 → Jun 2019 | osteoarthritis, knee | Yooyoung Pharmaceutical Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YYD302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02965495 ↗ |
| Modality | Other / unclassified | “novel divinyl sulfone cross-linked hyaluronate (YYD302)” PMID 34736768 ↗ Nov 2021 |
| Route | Other | “Intra-Articular Injection of a Novel DVS Cross-Linked Hyaluronic Acid Manufactured by Biological Fermentation (YYD302)” PMID 34736768 ↗ Nov 2021 |